Citigroup Inc. Has $14.42 Million Stock Holdings in ICU Medical, Inc. $ICUI

Key Points

• Citigroup Inc. increased its stake in ICU Medical by 220.7%, acquiring an additional 71,435 shares, bringing its total to 103,806 shares valued at approximately $14.4 million.
• Several other institutional investors, including Wells Fargo and Russell Investments Group Ltd., also boosted their holdings in ICU Medical, indicating strong interest from institutional players.
• ICU Medical's quarterly financial performance surpassed expectations with an EPS of $2.10, above the estimated $1.44, even as revenue declined by 8% year-over-year.

Citigroup Inc. increased its position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 220.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 103,806 shares of the medical instruments supplier's stock after purchasing an additional 71,435 shares during the quarter. Citigroup Inc. owned approximately 0.42% of ICU Medical worth $14,415,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ICUI. GAMMA Investing LLC raised its holdings in shares of ICU Medical by 17,559.7% in the 1st quarter. GAMMA Investing LLC now owns 99,424 shares of the medical instruments supplier's stock valued at $138,060,000 after purchasing an additional 98,861 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of ICU Medical by 63.2% in the 4th quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock valued at $38,069,000 after purchasing an additional 95,030 shares during the period. Pacific Capital Partners Ltd bought a new stake in shares of ICU Medical in the 1st quarter valued at about $12,845,000. Dimensional Fund Advisors LP raised its holdings in shares of ICU Medical by 18.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock valued at $83,788,000 after purchasing an additional 82,982 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of ICU Medical by 11.1% in the 4th quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier's stock valued at $62,431,000 after purchasing an additional 40,187 shares during the period. 96.10% of the stock is owned by institutional investors.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI traded up $1.21 on Tuesday, reaching $124.17. 50,099 shares of the company's stock were exchanged, compared to its average volume of 266,131. The company has a fifty day moving average of $127.94 and a 200-day moving average of $137.73. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $196.26. The company has a market capitalization of $3.07 billion, a price-to-earnings ratio of -81.61 and a beta of 0.88. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. During the same quarter in the prior year, the business posted $1.56 EPS. The business's revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ICUI shares. Wall Street Zen cut shares of ICU Medical from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Raymond James Financial lowered their price target on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a report on Friday, August 8th. KeyCorp lowered their price target on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Finally, Piper Sandler initiated coverage on shares of ICU Medical in a report on Friday. They issued an "overweight" rating and a $145.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $179.00.

Insider Buying and Selling

In other ICU Medical news, COO Christian B. Voigtlander sold 4,985 shares of the stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $128.50, for a total transaction of $640,572.50. Following the transaction, the chief operating officer owned 6,088 shares in the company, valued at $782,308. This represents a 45.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain purchased 21,929 shares of ICU Medical stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the transaction, the chief executive officer directly owned 130,149 shares in the company, valued at $14,686,013.16. This represents a 20.26% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 14,889 shares of company stock worth $1,933,186. Company insiders own 1.50% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.